Accumulating evidence has demonstrated that aberrant expression and activity of STAT3 is implicated in both carcinogenesis and development of drug resistance in several cancer types, including NSCLC [10-15], suggesting that STAT3 may contribute to resistance to EGFR TKI treatment in lung cancer. This evidence concerns the gene EGFR and lung cancer.